FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054298919> ?p ?o ?g. }

• W2054298919 endingPage "93" @default.
• W2054298919 startingPage "89" @default.
• W2054298919 abstract "The primary objective of this study was to determine the objective response rate of bortezomib as a first-line therapy in patients advanced stage NSCLC. Advanced/metastatic NSCLC patients with measurable disease, adequate organ function, ECOG performance status of 0-2, and no prior chemotherapy for metastatic disease were eligible. Patients received intravenously bolus bortezomib 1.3mg/m(2)/day on days 1, 4, 8 and 11 every 21 days for a maximum of 8 cycles, or until disease progression, or unacceptable toxicity. Tumor response was evaluated after every 2 cycles of therapy. This single-arm phase II study employed the Simon's two-stage design. The study was terminated in the first stage after 14 patients enrolled at 4 institutions. No objective response was observed. Three patients (21%) had stable disease and received 8, 6 and 4 cycles of treatment; the duration of stable disease was 11.5, 4.2 and 3.4 months, respectively. Median time to progression was 1.3 months (95% CI, 0.6-3.0 months); median overall survival (OS) was 9.9 months (95% CI, 2.2-27.0 months). Twelve patients received at least one dose of bortezomib. There were no grade 4 toxicities or treatment related deaths. Grade 3 toxicities included fatigue (N=1, 8%), deep vein thrombosis (N=1, 8%) and thrombocytopenia (N=1, 8%). Although well tolerated, bortezomib monotherapy is not active in this cohort of chemotherapy-naïve, metastatic NSCLC." @default.
• W2054298919 created "2016-06-24" @default.
• W2054298919 creator A5016048055 @default.
• W2054298919 creator A5020397680 @default.
• W2054298919 creator A5034912444 @default.
• W2054298919 creator A5045531429 @default.
• W2054298919 creator A5050480432 @default.
• W2054298919 creator A5056462542 @default.
• W2054298919 creator A5063025231 @default.
• W2054298919 creator A5077391276 @default.
• W2054298919 date "2010-04-01" @default.
• W2054298919 modified "2023-10-18" @default.
• W2054298919 title "Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)" @default.
• W2054298919 cites W1967578320 @default.
• W2054298919 cites W1990185409 @default.
• W2054298919 cites W2000044224 @default.
• W2054298919 cites W2020313926 @default.
• W2054298919 cites W2029409133 @default.
• W2054298919 cites W2030720872 @default.
• W2054298919 cites W2031403784 @default.
• W2054298919 cites W2032332769 @default.
• W2054298919 cites W2037139573 @default.
• W2054298919 cites W2053393533 @default.
• W2054298919 cites W2110689098 @default.
• W2054298919 cites W2134271760 @default.
• W2054298919 cites W2136951601 @default.
• W2054298919 cites W2139248078 @default.
• W2054298919 cites W2144660856 @default.
• W2054298919 cites W2145835533 @default.
• W2054298919 cites W2149569497 @default.
• W2054298919 cites W2156470208 @default.
• W2054298919 cites W4246943586 @default.
• W2054298919 doi "https://doi.org/10.1016/j.lungcan.2009.05.009" @default.
• W2054298919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19524318" @default.
• W2054298919 hasPublicationYear "2010" @default.
• W2054298919 type Work @default.
• W2054298919 sameAs 2054298919 @default.
• W2054298919 citedByCount "39" @default.
• W2054298919 countsByYear W20542989192012 @default.
• W2054298919 countsByYear W20542989192013 @default.
• W2054298919 countsByYear W20542989192014 @default.
• W2054298919 countsByYear W20542989192015 @default.
• W2054298919 countsByYear W20542989192017 @default.
• W2054298919 countsByYear W20542989192018 @default.
• W2054298919 countsByYear W20542989192019 @default.
• W2054298919 countsByYear W20542989192020 @default.
• W2054298919 countsByYear W20542989192021 @default.
• W2054298919 crossrefType "journal-article" @default.
• W2054298919 hasAuthorship W2054298919A5016048055 @default.
• W2054298919 hasAuthorship W2054298919A5020397680 @default.
• W2054298919 hasAuthorship W2054298919A5034912444 @default.
• W2054298919 hasAuthorship W2054298919A5045531429 @default.
• W2054298919 hasAuthorship W2054298919A5050480432 @default.
• W2054298919 hasAuthorship W2054298919A5056462542 @default.
• W2054298919 hasAuthorship W2054298919A5063025231 @default.
• W2054298919 hasAuthorship W2054298919A5077391276 @default.
• W2054298919 hasConcept C126322002 @default.
• W2054298919 hasConcept C141071460 @default.
• W2054298919 hasConcept C143998085 @default.
• W2054298919 hasConcept C2776256026 @default.
• W2054298919 hasConcept C2776364478 @default.
• W2054298919 hasConcept C2776694085 @default.
• W2054298919 hasConcept C2776907518 @default.
• W2054298919 hasConcept C2777478702 @default.
• W2054298919 hasConcept C2778367456 @default.
• W2054298919 hasConcept C2778822529 @default.
• W2054298919 hasConcept C71924100 @default.
• W2054298919 hasConcept C90924648 @default.
• W2054298919 hasConceptScore W2054298919C126322002 @default.
• W2054298919 hasConceptScore W2054298919C141071460 @default.
• W2054298919 hasConceptScore W2054298919C143998085 @default.
• W2054298919 hasConceptScore W2054298919C2776256026 @default.
• W2054298919 hasConceptScore W2054298919C2776364478 @default.
• W2054298919 hasConceptScore W2054298919C2776694085 @default.
• W2054298919 hasConceptScore W2054298919C2776907518 @default.
• W2054298919 hasConceptScore W2054298919C2777478702 @default.
• W2054298919 hasConceptScore W2054298919C2778367456 @default.
• W2054298919 hasConceptScore W2054298919C2778822529 @default.
• W2054298919 hasConceptScore W2054298919C71924100 @default.
• W2054298919 hasConceptScore W2054298919C90924648 @default.
• W2054298919 hasIssue "1" @default.
• W2054298919 hasLocation W20542989191 @default.
• W2054298919 hasLocation W20542989192 @default.
• W2054298919 hasOpenAccess W2054298919 @default.
• W2054298919 hasPrimaryLocation W20542989191 @default.
• W2054298919 hasRelatedWork W1801735820 @default.
• W2054298919 hasRelatedWork W1978433927 @default.
• W2054298919 hasRelatedWork W2076028786 @default.
• W2054298919 hasRelatedWork W2147486721 @default.
• W2054298919 hasRelatedWork W2156470208 @default.
• W2054298919 hasRelatedWork W2367225000 @default.
• W2054298919 hasRelatedWork W2570112540 @default.
• W2054298919 hasRelatedWork W2979590512 @default.
• W2054298919 hasRelatedWork W3031381806 @default.
• W2054298919 hasRelatedWork W2183750618 @default.
• W2054298919 hasVolume "68" @default.
• W2054298919 isParatext "false" @default.
• W2054298919 isRetracted "false" @default.

• next